These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25274033)

  • 21. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
    Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
    Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
    Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
    Fong KW; Zhao JC; Song B; Zheng B; Yu J
    Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
    Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
    Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
    Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
    J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer.
    Burleson M; Deng JJ; Qin T; Duong TM; Yan Y; Gu X; Das D; Easley A; Liss MA; Yew PR; Bedolla R; Kumar AP; Huang TH; Zou Y; Chen Y; Chen CL; Huang H; Sun LZ; Boyer TG
    Mol Cancer Res; 2022 Jan; 20(1):62-76. PubMed ID: 34610962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deregulation of SPOP in Cancer.
    Zhang H; Jin X; Huang H
    Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
    Hess-Wilson JK; Webb SL; Daly HK; Leung YK; Boldison J; Comstock CE; Sartor MA; Ho SM; Knudsen KE
    Environ Health Perspect; 2007 Nov; 115(11):1646-53. PubMed ID: 18007998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
    Mani RS
    Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
    Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
    Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
    Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
    Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
    Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
    J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
    Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
    Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments.
    Bouchard JJ; Otero JH; Scott DC; Szulc E; Martin EW; Sabri N; Granata D; Marzahn MR; Lindorff-Larsen K; Salvatella X; Schulman BA; Mittag T
    Mol Cell; 2018 Oct; 72(1):19-36.e8. PubMed ID: 30244836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
    Zhu H; Ren S; Bitler BG; Aird KM; Tu Z; Skordalakes E; Zhu Y; Yan J; Sun Y; Zhang R
    Cell Rep; 2015 Nov; 13(6):1183-1193. PubMed ID: 26527005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.